9 Meters Biopharma, Inc. (NMTR)
Stock Price:
$1.07 USD
-0.02 (-1.83%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $1.05 -0.02 (-1.87%) Nov 27, 4:49 PM
Key Info
| Market Cap |
160.85M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-65.44M |
| Shares Out |
150.32M |
| EPS (ttm) |
-0.97 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$1.07 |
| Previous Close |
$1.09 |
| Change ($) |
-0.02 |
| Change (%) |
-1.83% |
| Day's Open |
1.09 |
| Day's Range |
1.04 - 1.10 |
| Day's Volume |
1,470,088 |
| 52-Week Range |
0.39 - 1.11 |
More Stats
| Market Cap |
160.85M |
| Enterprise Value |
149.78M |
| Earnings Date (est) |
Jan 1, 1970 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
150.32M |
| Float |
n/a |
| EPS (basic) |
-0.97 |
| EPS (diluted) |
-0.97 |
| FCF / Share |
-0.12 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
4.16M |
| Short Ratio |
2.55 |
| Short % of Float |
n/a |
| Beta |
-0.40 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
40.17 |
| Revenue |
n/a |
| Operating Income |
-56.28M |
| Net Income |
-65.44M |
| Free Cash Flow |
-16.22M |
| Net Cash |
11.07M |
| Net Cash / Share |
0.07 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-123.93% |
| ROE |
-42,818.92% |
| ROIC |
698.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$4.00*
(273.83% upside)
Low
3.00
Current: $1.07
High
5.00
Target: 4.00
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | - | - | - | 4.07 | 8.27 | 11.34 |
| Revenue Growth | - | - | - | -50.82% | -27.13% | - |
| Gross Profit | - | - | - | 0.74 | 0.43 | 0.23 |
| Operating Income | -24.28 | -18.22 | -11.17 | -5.94 | -6.46 | -6.68 |
| Net Income | -27.05 | -24.16 | -11.61 | -6.21 | -8.74 | -11.06 |
| Shares Outstanding | 33.33 | 24.76 | 11.89 | 0.55 | 0.33 | 0.28 |
| Earnings Per Share | -0.81 | -0.98 | -0.98 | -11.26 | -26.50 | -39.50 |
| Operating Cash Flow | -17.97 | -15.17 | -5.10 | -8.43 | -1.73 | -7.45 |
| Capital Expenditures | -0.01 | -0.01 | -0.04 | - | - | - |
| Free Cash Flow | -17.98 | -15.18 | -5.14 | -8.43 | -1.73 | -7.45 |
| Cash & Equivalents | 4.67 | 5.80 | 0.36 | 1.45 | 0.12 | 0.10 |
| Total Debt | 3.18 | 5.20 | 8.57 | 0.04 | 3.72 | 5.09 |
| Net Cash / Debt | 1.48 | 0.61 | -8.22 | 1.42 | -3.60 | -4.99 |
| Assets | 5.30 | 6.45 | 0.80 | 6.46 | 4.72 | 6.41 |
| Liabilities | 14.91 | 10.11 | 12.97 | 3.98 | 10.41 | 11.40 |
| Book Value | -9.61 | -3.66 | -12.17 | 2.49 | -5.69 | -4.99 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
9 Meters Biopharma, Inc. |
| Country |
United States |
| Employees |
8 |
| CEO |
John Temperato |
Stock Information
| Ticker Symbol |
NMTR |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: NMTR |
Description
9 Meters Biopharma, a clinical-stage biotechnology company, focuses on patients with rare disorders and unmet needs. The company's pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease. It is developing NM-002, a long-acting injectable GLP-1 agonist that is in a Phase 2 clinical trial for SBS; and Larazotide, a Phase 3-stage therapeutic in development for celiac disease. The company also develops NM-003, a proprietary long-acting GLP-2 agonist; and NM-004, a double-cleaved mesalamine with an immunomodulator for developing rare and/or orphan indications. 9 Meters Biopharma, Inc. is based in Raleigh, North Carolina.